Recap: Regulus Therapeutics Q2 Earnings

Shares of Regulus Therapeutics RGLS fell in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share increased 65.22% year over year to ($0.08), which were in line with the estimate of ($0.08).

Revenue of $0 unchanged by 0.00% from the same period last year, which missed the estimate of $10,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Aug 10, 2021

Time: 05:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/xnw8bbur

Technicals

52-week high: $2.32

52-week low: $0.42

Price action over last quarter: down 18.18%

Company Overview

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!